Table 3.
Predictive value of pretreatment variables and initial gene expressions (fold difference in comparison with healthy controls) for SVR achievement
| Odds ratio | 95% CI | |
|---|---|---|
| IL28B genotype CT vs TT | 4.33 | 0.68–28.11 |
| HCV RNA <600,000 IU/mL | 3.50 | 0.35–35.37 |
| Age <50 years | 2.40 | 0.38–15.28 |
| Sex (male/female) | 0.52 | 0.08–3.36 |
| DAA (BOC vs TVR) | 0.60 | 0.11–3.30 |
| Metavir score (F3 vs F4) | 3.00 | 0.47–19.04 |
| Previous treatment (REL vs NR) | 5.60 | 0.57–55.43 |
| CXCL9 >2.03 | 12.00 | 1.21–118.89 |
| IFI16 >14.10 | 0.73 | 0.14–3.82 |
| IFI27 >4.00 | 12.00 | 1.21–118.89 |
| IFNG >1.34 | 10.50 | 1.50–73.67 |
| IFNLR1 >0.90 | 1.81 | 0.35–9.24 |
| ISG15 >2.80 | 1.25 | 0.24–6.63 |
| USP18 >1.74 | 21.00 | 2.05–215.18 |
Abbreviations: BOC, boceprevir; DAA, direct-acting antiviral; HCV, hepatitis C virus; NR, non-response; REL, relapse; SVR, sustained virological response; TVR, telaprevir.